Theravance Biopharma Ireland Ltd., a unit of Theravance Biopharma Inc., is set to receive $100 million from Janssen Biotech Inc., a subsidiary of New Brunswick, N.J.-based Johnson & Johnson, as part of a global co-development and commercialization deal for TD-1473. The oral, intestinally restricted pan-Janus kinase (JAK) inhibitor targets inflammatory intestinal diseases, including ulcerative colitis (UC) and Crohn's disease.
Vertex Pharmaceuticals Inc. reported solid fourth-quarter and full-year 2017 financial results, pleasing analysts, but what really got their attention was the company's selection of next-generation correctors, VX-659 and VX-445, for phase III development as part of separate triple-combination regimens for individuals with cystic fibrosis (CF).
Ubrogepant, the oral calcitonin gene-related peptide (CGRP) receptor antagonist from Allergan plc, hit the co-primary efficacy endpoints in ACHIEVE I, the first of two pivotal phase III trials evaluating the candidate to treat acute migraine in adults. Both 50-mg and 100-mg doses showed a statistically significant difference in the percentage of individuals treated with ubrogepant who achieved pain freedom two hours after the initial dose compared to placebo (50 mg vs. placebo, p=0.0023, 100 mg vs. placebo, p=0.0003) – response rates of about 19 percent and 21 percent, respectively, for the treatment arms compared to 12 percent for placebo.
Top-line results from Eyegate Pharmaceuticals Inc.'s phase IIb study of combination drug/device candidate EGP-437 to treat pain and inflammation in patients following cataract surgery hit a familiar stumbling block.
Seattle Genetics Inc. (Seagen) showed it fully recovered from last year’s ill-fated pact with Immunomedics Inc. by nabbing Cascadian Therapeutics Inc. – lock, stock and barrel – for $10 per share in cash, valuing the transaction at approximately $614 million.
Talk with the administrators of any given U.S. hospital system, and you'll hear their frustration over shortages of essential medications developed in the 1950s, '60s and '70s – long off-patent – plaguing the U.S. health care system.
Talk with the administrators of any given U.S. hospital system, and you'll hear their frustration over shortages of essential medications developed in the 1950s, '60s and '70s – long off-patent – plaguing the U.S. health care system.
It's been a heady January for biopharma financings, but talk of frothy markets is certain to escalate after Solid Biosciences Inc. salvaged its offering with some fancy footwork, pricing 7.8 million common shares at $16 apiece to gross $125 million. Solid, of Cambridge, Mass., originally planned to offer 5.9 million shares priced in a range of $16 to $18, setting its sights on a raise of about $100 million.
Biogen Inc. reported 2017 revenues of $12.3 billion, a 7 percent increase compared to full-year 2016 revenues or an increase of 15 percent when revenues from hemophilia assets – ceded last year to spinout Bioverativ Inc. – were excluded.
